INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease with Inflammation
Reuters
Sep 29
INmune Bio Announces Positive Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer's Disease with Inflammation
INmune Bio Inc. has announced the submission of results from its Phase 2 MINDFuL trial evaluating XPro™, a selective soluble TNF neutralizer, in patients with early Alzheimer's disease and inflammation. The manuscript, titled "XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer's Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial," has been submitted for peer review to npj Dementia, a Nature Portfolio journal. According to the company, the trial demonstrated positive trends in cognitive, neuropsychiatric, and biological endpoints in a prespecified subgroup of patients with both amyloid pathology and a high inflammatory burden. While the primary endpoint was not met in the overall population, a promising signal was observed in this biomarker-enriched ADi subgroup. The results have been made available as a preprint on medRxiv and are pending further peer-reviewed publication.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9536487-en) on September 29, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.